Given that midazolam inhibits HOOK3 in NSCLC cells, and HOOK3 is closely associated with cancer progression [26], it was reasonable to hypothesize that midazolam might regulate cisplatin-resistance in NSCLC via HOOK3. The gene discussed is HOOK3; the disease is cancer.